SCHEMBL12468575

SCHEMBL12468575

O=S(=O)(O)CCOc1ccc(OCCS(=O)(=O)O)cc1.[NaH]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
LMNA P02545 2/20 0.50
POLB P06746 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 2/20 0.50
PKM P14618 2/20 0.50
NPC1 O15118 1/20 0.50
ALOX15 P16050 1/20 0.50
BRCA1 P38398 1/20 0.50
HTT P42858 1/20 0.50
KDM4E B2RXH2 1/20 0.50
GMNN O75496 1/20 0.50
THPO P40225 1/20 0.50
MTOR P42345 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
HIF1A Q16665 1/20 0.50
LTA4H P09960 1/20 0.45
S1PR1 P21453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17274189 0.98 ALDH1A1 (0.51) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL11204077 0.92 LTA4H (0.47) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL3364133 0.90 KCNA3 (0.52) ALDH1A1RAB9ASMN1; SMN2PKMNPC1
SCHEMBL28319542 0.88 TAAR1 (0.50) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL6451025 0.88 ALDH1A1 (0.49) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL19846329 0.88 ALDH1A1 (0.45) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL25737139 0.88 ALDH1A1 (0.45) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL3459447 0.88 KMT2A (0.47) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL6595731 0.88 ALDH1A1 (0.45) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2
SCHEMBL14557453 0.88 L3MBTL1 (0.55) ALDH1A1LMNAPOLBRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3207046-B1 ACYCLIC CUCURBIT(N)URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS UNIV MARYLAND (US) 2024-09-25 EP disclosed
US-20240124476-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2024-04-18 US disclosed
US-11897893-B2 Molecular containers and methods of making and using same UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2024-02-13 US disclosed
US-20210206774-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2021-07-08 US disclosed
US-9956229-B2 Acyclic cucurbit[n]uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2018-05-01 US disclosed
US-20170246180-A1 ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS GENERAL HOSPITAL CORPORATION 2017-08-31 US disclosed
EP-3207046-A1 ACYCLIC CUCURBIT(N)URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS University of Maryland, College Park (US) 2017-08-23 EP disclosed
US-20170137431-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2017-05-18 US disclosed
US-9566351-B2 Molecular containers and methods of making and using same UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2017-02-14 US disclosed
US-9567344-B2 Molecular containers and methods of making and using same UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2017-02-14 US disclosed
US-9469648-B2 Reversal of drug-induced neuromuscular block using novel molecular containers UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2016-10-18 US disclosed
WO-2016061571-A1 ACYCLIC CUCURBIT(N)URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2016-04-21 WO disclosed
EP-2627657-B1 CUCURBIT[n]URIL-TYPE MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME UNIV MARYLAND (US) 2016-02-03 EP disclosed
EP-2627641-B1 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL CUCURBIT[n]URIL MOLECULAR CONTAINERS UNIV MARYLAND (US) 2016-01-20 EP disclosed
US-20150328334-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME UNIVERSITY OF MARYLAND 2015-11-19 US disclosed
US-20130345273-A1 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS GENERAL HOSPITAL CORPORATION (US) 2013-12-26 US disclosed
EP-2627641-A1 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS University of Maryland, College Park (US) 2013-08-21 EP disclosed
EP-2627657-A2 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME University of Maryland, College Park (US) 2013-08-21 EP disclosed
WO-2012051407-A2 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2012-04-19 WO disclosed
WO-2012051413-A1 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345273-A1 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS CHRNA10, CHRNB4, CHRNA4 ALDH1A1 2499/4885LMNA 702/4885POLB 2192/4885
US-11897893-B2 Molecular containers and methods of making and using same CBR1, CNR1, CNR2 ALDH1A1 466/4885LMNA 651/4885POLB 1502/4885
US-20170137431-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME CBR1, CNR1, CNR2 ALDH1A1 466/4885LMNA 651/4885POLB 1502/4885
US-20150328334-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME CBR1, CNR1, CNR2 ALDH1A1 466/4885LMNA 651/4885POLB 1502/4885
US-20170246180-A1 ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS CNR1, CNR2, OPRM1 ALDH1A1 74/4885LMNA 3286/4885POLB 2720/4885
US-20210206774-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME CBR1, CNR1, CNR2 ALDH1A1 466/4885LMNA 651/4885POLB 1502/4885
US-20240124476-A1 MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME CBR1, CNR1, CNR2 ALDH1A1 466/4885LMNA 651/4885POLB 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.